Retraction to: Cell Biosci (2018) 8:17 https://doi.org/10.1186/s13578-018-0212-8
The Editor-in-Chief has retracted this paper. After publication, concerns were raised around the similarity between the rightmost ACHN panel of Fig. 4f and the TGF-B1 + Celecoxib panel in Fig. 5B in a previously-published article by different authors [1]. The Editor-in-Chief therefore no longer has confidence in the results and conclusions of this article. The authors have not responded to any correspondence from the editor about this retraction.
Reference
Cha BK, Kim YS, Hwang KE, Cho KH, Oh SH, Kim BR, Jun HY, Yoon KH, Jeong ET, Kim HR. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget 2016; 7(35): 57213. https://doi.org/10.18632/oncotarget.11127
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Li, T., Sun, X. & Xu, K. Retraction Note: The suppressing role of miR-622 in renal cell carcinoma progression by down-regulation of CCL18/MAPK signal pathway. Cell Biosci 13, 27 (2023). https://doi.org/10.1186/s13578-023-00976-x
Published:
DOI: https://doi.org/10.1186/s13578-023-00976-x